Crypto’s Hidden Gem: The missing piece no one’s talking about

You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.

Click Here to get the full details about Crypto’s Hidden Gem

Richard A. Heyman net worth and biography

Richard Heyman Biography and Net Worth

Director of ORIC Pharmaceuticals

Dr. Heyman has over 25 years of biopharma experience. Previously, he was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, two San Diego biotech companies focused on discovering and developing therapeutics targeting hormone-dependent cancers. Johnson & Johnson purchased Aragon in 2013 and Genentech/Roche purchased Seragon in 2014.

Earlier in his career, Dr. Heyman was co-founder and Chief Scientific Officer of X-Ceptor Therapeutics, and also served as Vice President of Research at Ligand Pharmaceuticals. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the recently approved drug, Erleada®, that was demonstrated to increase progression-free survival for prostate cancer patients. He is the author or inventor on more than 120 publications and patents. In addition to serving on the board of directors for ORIC, Dr. Heyman also serves on the board of directors for Gritstone Oncology, Yumanity Therapeutics, Metacrine, Vividion Therapeutics and Mavu Pharma. He is also the Vice Chairman of The Salk Institute. He was an NIH postdoctoral fellow at the Salk Institute, and received a PhD in pharmacology from the University of Minnesota and a BS in chemistry from the University of Connecticut.

What is Richard A. Heyman's net worth?: The estimated net worth of Richard A. Heyman is at least $1.03 million as of October 18th, 2024. Dr. Heyman owns 123,673 shares of ORIC Pharmaceuticals stock worth more than $1,031,433 as of November 15th. This net worth evaluation does not reflect any other investments that Dr. Heyman may own. Additionally, Dr. Heyman receives an annual salary of $93,000.00 as Director at ORIC Pharmaceuticals. Learn More about Richard A. Heyman's net worth.
How old is Richard A. Heyman?: Dr. Heyman is currently 67 years old. There are 7 older executives and no younger executives at ORIC Pharmaceuticals. Learn More on Richard A. Heyman's age.
What is Richard A. Heyman's salary?: As the Director of ORIC Pharmaceuticals, Inc., Dr. Heyman earns $93,000.00 per year. There are 3 executives that earn more than Dr. Heyman. The highest earning executive at ORIC Pharmaceuticals is Dr. Jacob M. Chacko M.B.A., M.D., President, CEO & Director, who commands a salary of $961,000.00 per year. Learn More on Richard A. Heyman's salary.
How do I contact Richard A. Heyman?: The corporate mailing address for Dr. Heyman and other ORIC Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. ORIC Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected]. Learn More on Richard A. Heyman's contact information.
Has Richard A. Heyman been buying or selling shares of ORIC Pharmaceuticals?: Richard A. Heyman has not been actively trading shares of ORIC Pharmaceuticals in the last ninety days. Learn More on Richard A. Heyman's trading history.
Who are ORIC Pharmaceuticals' active insiders?: ORIC Pharmaceuticals' insider roster includes Jacob Chacko (CEO), Carl Gordon (Director), Richard Heyman (Director), and Richard Scheller (Director). Learn More on ORIC Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ORIC Pharmaceuticals?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 33,779 shares worth more than $339,287.96. The most recent insider tranaction occured on February, 6th when CEO Jacob Chacko sold 13,958 shares worth more than $169,170.96. Insiders at ORIC Pharmaceuticals own 5.6% of the company. Learn More about insider trades at ORIC Pharmaceuticals.
Information on this page was last updated on 2/6/2024.

Richard A. Heyman Insider Trading History at ORIC Pharmaceuticals

Richard A. Heyman Buying and Selling Activity at ORIC Pharmaceuticals

ORIC Pharmaceuticals Company Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $8.36

$8.10

$9.05

50 Day Range

MA: $9.72

$8.15

$11.25

2 Week Range

Now: $8.36

$6.33

$16.65

Volume

440,416 shs

Average Volume

517,858 shs

Market Capitalization

$589.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

My Top Trump Rally Stocks

From StocksToTrade | Ad

This Catalyst Hits Once Every 4 Years.. Every four years, on the day of the election, a catalyst is triggered. Over the last 20 years, this catalyst has caused 1,500 stocks to rise an average of 3,700%... within 90 days. And now, Tim Bohen is blowing the whole story wide open on Wednesday, November 20th at 8PM.

Click here for details on your FREE RSVP.

Richard Heyman Biography and Net Worth

What is Richard A. Heyman's net worth?

How old is Richard A. Heyman?

What is Richard A. Heyman's salary?

How do I contact Richard A. Heyman?

Has Richard A. Heyman been buying or selling shares of ORIC Pharmaceuticals?

Who are ORIC Pharmaceuticals' active insiders?

Are insiders buying or selling shares of ORIC Pharmaceuticals?